




RealRate

PHARMACEUTICAL 2018

MELINTA THERAPEUTICS INC. NEW
Rank 146 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

MELINTA THERAPEUTICS INC. NEW Rank 146 of 349

The relative strengths and weaknesses of MELINTA THERAPEUTICS INC. NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MELINTA THERAPEUTICS INC. NEW compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 110% points. The greatest weakness of MELINTA THERAPEUTICS INC. NEW is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -129%, being 149% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	149,764
Cost of Goods Sold	0
Intangible Assets	7,500
Liabilities, Current	31,730
Liabilities, Non-Current	56,207
Other Assets	1,413
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	20,020
Property and Equipment	1,596
Research and Development	49,475
Revenues	33,864
Selling, General and Administrative Expense	63,325

Output Variable	Value in 1000 USD
Assets	160,273
Liabilities	87,937
Expenses	112,800
Stockholders Equity	72,336
Net Income	-58,916
Comprehensive Net Income	-58,916
Economic Capital Ratio	-129%

